BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017

Mar 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-03-10

Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-10	Common Stock	M	3250	$3.78	Acquired	120563	Direct
2017-03-10	Common Stock	S	3250	$9.06	Disposed	117313	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-10	Emp. Stock Option (Right to Buy)	$3.78	M	3250	Disposed	2021-07-01	Common Stock (3250)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016.

F2: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.02 to $9.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.